Whereas immune checkpoint antibody therapy has not yet been studied in ampullary cancer, anti-PD-L1 antibodies and anti-CTLA-4 antibodies have been found to be clinically ineffective in pancreatic cancer (14, 15). Here, CD274 is linked to familial pancreatic carcinoma.